March 14, 2025 03:00 PM EDT
R&D

Boston Phar­ma, build­ing off MASH mo­men­tum, mulls an IPO ahead of Phase 3 tri­al

Max Bayer

Pharma Reporter

The once-fledg­ling field of MASH drug de­vel­op­ers is now one of the few ar­eas of con­sis­ten­cy in the biotech in­dus­try.

And an­oth­er late-stage start­up is …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Big leas­es, big­ger re­grets: Biotech slump turns swanky of­fices from as­set in­to li­a­bil­i­ty

FDA asks Covid vac­cine mak­ers to add more my­ocardi­tis da­ta to la­bels

Hinge Health is go­ing pub­lic on Thurs­day at a $3B val­u­a­tion

Up­dat­ed: Eikon Ther­a­peu­tics cuts staff for the sec­ond time in less than two years

Al­tos Labs buys an­ti-ag­ing start­up Do­ri­an Ther­a­peu­tics

sponsored

Does your sup­ply chain hold up un­der pres­sure for high-risk tem­per­a­ture-crit­i­cal ship­ments?

A service from the Financial Times